What are the treatment options for osteoporosis in a patient with jaw disease (e.g., medication‑related osteonecrosis of the jaw)?

Treatment Options for Osteoporosis with Jaw Disease

In patients with osteoporosis who have developed medication-related osteonecrosis of the jaw (MRONJ), switch to teriparatide (anabolic therapy) followed by raloxifene (selective estrogen receptor modulator) as the preferred treatment sequence, avoiding bisphosphonates and denosumab to prevent MRONJ recurrence while maintaining fracture protection.

Primary Treatment Strategy

The most recent real-world evidence from a tertiary center demonstrates that teriparatide followed by raloxifene represents the most reasonable regimen for osteoporosis management after MRONJ occurrence 1. This sequence achieved stable or improving bone mineral density (BMD) in 7 of 8 patients treated with this approach, with only one patient showing a mixed response (who had also been exposed to denosumab) 1.

Why This Approach Works

• Avoids antiresorptive agents: Both bisphosphonates and denosumab are directly implicated in MRONJ pathogenesis and recurrence 2
• Maintains fracture protection: Anabolic therapy (teriparatide) actively builds bone rather than just preventing resorption
• Sequential therapy: Raloxifene maintains gains after teriparatide without the MRONJ risk associated with bisphosphonates or denosumab 1

Critical Decision Points

If MRONJ is Active (Stages 1-3)

Stage 1 (exposed bone, asymptomatic):

• Antibacterial mouth rinse
• Patient education
• Avoid surgical intervention
• 8-week follow-up intervals with dental specialist 3

Stage 2 (exposed bone with infection):

• Oral antibiotics
• Topical antibacterial rinse
• Pain control
• Limited debridement only for soft tissue irritation
• 8-week dental specialist follow-up 3

Stage 3 (extensive necrosis with complications):

• Oral antibiotics and topical rinse
• Surgical debridement or resection for long-term palliation
• Pain management
• 8-week dental specialist follow-up 3

Regarding Antiresorptive Drug Discontinuation

For bisphosphonates: Discontinuation at MRONJ diagnosis is unlikely to affect outcomes due to the extremely long half-life in bone 3. However, do not restart bisphosphonates as this is associated with MRONJ recurrence 1.

For denosumab: Temporary discontinuation may enhance MRONJ resolution due to shorter plasma half-life, but this must be weighed against skeletal-related event risk 3. Do not restart denosumab as recurrence occurred in patients who resumed this medication 1.

Fracture Risk Management

High-Risk Patients

Patients with higher fracture probability at MRONJ onset are more likely to continue anti-osteoporosis treatment 1. The decision to treat is influenced by:

• Lower BMD T-scores: Six patients who sustained incident fractures after MRONJ had significantly lower BMD than those without fractures 1
• Prior fracture history
• Age and comorbidities

Treatment Algorithm

1. Assess fracture risk: Use BMD T-scores, prior fractures, and clinical risk factors
2. If very high fracture risk: Initiate teriparatide (anabolic agent) 2, 1
3. After teriparatide course (typically 18-24 months): Transition to raloxifene to preserve gains 1
4. Avoid: Bisphosphonates and denosumab indefinitely due to MRONJ recurrence risk 1

Alternative Consideration: Romosozumab

For patients at very high fracture risk, romosozumab (sclerostin inhibitor) followed by a non-bisphosphonate agent could be considered 2. However:

• Evidence shows romosozumab followed by alendronate, but alendronate should be avoided in MRONJ patients
• Could potentially use romosozumab followed by raloxifene, though this specific sequence lacks direct evidence
• Romosozumab has moderate evidence for not increasing serious harms 2

Critical Pitfalls to Avoid

1. Never restart bisphosphonates or denosumab after MRONJ—both are associated with recurrence 1
2. Do not delay osteoporosis treatment in high fracture-risk patients; fracture events occurred in untreated patients with lower BMD 1
3. Coordinate with dental specialists: Communication every 8 weeks regarding lesion status (resolved, improving, stable, or progressive) is essential 3
4. Recognize that full mucosal healing is not always achievable: Lesion stability may be an acceptable outcome 3

Preventive Dental Management

Before any dental procedures in patients on osteoporosis therapy:

• Tooth extraction is the strongest risk factor for MRONJ development (OR 9.74) 4
• Longer cumulative antiresorptive duration increases risk (OR 1.03 per month) 4
• Prophylactic dental care and good oral hygiene reduce MRONJ likelihood 5

Monitoring Strategy

• Dental specialist follow-up: Every 8 weeks during active MRONJ treatment 3
• BMD monitoring: Regular assessment to ensure treatment efficacy with teriparatide-raloxifene sequence 1
• Fracture surveillance: Particularly in patients with lower baseline BMD T-scores 1